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Abstract 
Interoception has recently come under research focus as a potential influence on 
emotional and epistemic feelings. However, existing means to manipulate it 
experimentally have conceptual or logistical drawbacks. We investigated whether 20 mg 
of propranolol is a viable agent for experimentally manipulating interoception. Thirteen 
participants completed a double-blind, placebo-controlled crossover study, performing 
two heartbeat perception tasks, control tasks and measures of anxiety and alertness. All 
measures were obtained at the beginning and end of both sessions. Propranolol 
significantly decreased heart rate and systolic blood pressure. Heartbeat detection 
performance numerically decreased under propranolol, although this effect failed to reach 
statistical significance. Heartbeat tracking exhibited a practice effect in both sessions. 
There were no significant effects on the control tasks. State anxiety was unchanged 
within either session, and alertness decreased in both. These findings validate the 
propranolol paradigm, and the numerical change in heartbeat detection warrants follow-
up with a larger sample. 
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Chapter 1  
1 Introduction 
The physiological state of the body influences the brain along two major dimensions. The 
first is metabolic and physiological support necessary for the maintenance of brain health 
and functioning. The second is moment-to-moment afferent signalling, used for 
homeostatic regulation, affective response, and, it has been argued, in generating and 
informing cognitive states (Critchley, Mathias, & Dolan, 2002). This second role relies 
on interoception, the ability to sense the physiological state of the body. Interoception 
subsumes the detection of any sensation arising from within the body, including “subtle 
changes in bodily systems including muscles, skin, joints and viscera” (Dunn et al, 2010). 
It can be contrasted with exteroception, which includes senses for the world outside the 
body, such as taste, smell and touch. It has been suggested that one function of 
interoception is to give rise to the subjective states we know as “feelings”, which can be 
defined as “mental experiences of body states” (Damasio & Carvalho, 2013). In bringing 
the current state of the organism to conscious awareness, it may aid in motivating 
appropriate action and inform decision making (Damasio & Carvalho, 2013).  
To date, research on the functional role of interoception has been largely confined to the 
domain of emotion. In particular, it is thought to be integral to the subjective experience 
of “feelings”. In a commonly held view, “feelings” are defined as a purely subjective 
experience, and are differentiable from “emotions”. The latter can be viewed as “innate 
physiological actions” in response to stimuli, for example, the changes in heart rate, 
breathing, and facial muscles constituting part of the overall emotion of fear (Damasio & 
Carvalho, 2013). In contrast, feelings are produced when interoceptive sensation of the 
physiological changes associated with emotion reaches conscious awareness (Damasio & 
Carvalho, 2013). Empirical research has implicated individual differences in 
interoception in modulating the intensity of conscious emotional experience. For 
example, Wiens, Mezzacappa & Katkin (2000) showed that good performers on a 
heartbeat perception task, an index of interoceptive ability, experienced emotional film 
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clips as being more arousing, as indexed by a self-report measure. Other studies have 
corroborated these findings (Pollatos, Kirsch & Schandry, 2005; Dunn et al., 2010).  
Although interoception need not be accompanied by conscious awareness, when it is, the 
resulting subjective experience, or “feeling”, has been proposed to play a role in the 
modulation or selection of the response to the stimulus precipitating the physiological 
change. In this way, feelings are thought to provide more flexibility in responding to 
one’s environment (Damasio & Carvalho, 2013; Wiens, 2005). However, “feelings” also 
play a role in non-emotional states, for example, as feelings of familiarity or feelings-of-
knowing in memory. Memory research has termed such states “epistemic feelings”, and 
evidence is mounting that they are functionally and mechanistically akin to the feelings 
we experience in emotion (Moulin & Souchay, 2013). Indeed, like emotional feelings, 
epistemic states are regarded as being fast, involuntary and subjective, as opposed to 
deliberative (Koriat, 2000). Additionally, a motivational framework has been described in 
which epistemic feelings can inform subsequent action, for example, in increasing search 
effort to retrieve information that is believed to be known, but cannot be accessed at the 
moment (e.g. the tip-of-the-tongue phenomenon) (Koriat, 2000). Given these parallels, 
the question of whether interoception can inform epistemic feelings presents a promising 
direction for future research. 
Interoception has been implicated in non-emotional cognition, in support of an 
“embodied cognition” view (Garfinkel, Seth, Barrett, Suzuki & Critchley, 2015). 
Preliminary evidence exists for a connection between interoception and memory 
judgments. Fiacconi et al. (2017) demonstrated a link between cardiac reactivity in 
response to novel and familiar faces, and the degree of change in participants’ feeling-of-
knowing judgments for the names associated with the faces. Critically, this relationship 
was moderated by individual differences in interoceptive ability. Interoception has also 
been linked to meta-memory confidence judgments (Garfinkel et al. 2013, Chua & Bliss-
Moreau, 2016) and decision-making (Dunn et al., 2010). These findings suggest that 
interoceptive perception of changes in bodily state can inform cognition, and epistemic 
feelings in particular, in addition to emotional experience. However, most of the work 
done to date has been correlational, linking inter-individual variation in interoceptive 
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ability to performance on cognitive tasks. To extend such findings, and establish a causal 
role for interoception in mediating between body states and epistemic feelings, it is 
necessary to both measure and manipulate interoceptive ability experimentally. The goal 
of the present study is to establish an experimental paradigm for the manipulation of 
interoceptive accuracy, which can in the future be used in conjunction with cognitive 
tasks to probe the role of interoception in memory and epistemic feelings. 
Interoception plays an important part in autonomic system regulation. Interoceptive 
pathways are involved in both sympathetic arousal and parasympathetic regulation, and 
play a role in diverse autonomic functions such as monitoring and regulation of blood 
pressure (Strigo & Craig, 2016), thermoregulation (Fealey, 2013) and physiological 
response to stress (Schulz & Vogele, 2015). Interoceptive signals are relayed to the 
human brain along two major pathways: the lamina I (spinothalamocortical) pathway and 
the vagus nerve. Both pathways ultimately project through the brainstem and thalamus to 
the insula and thereafter to diverse cortical structures. The lamina I pathway carries 
information about diverse body systems, including the organism’s thermoregulation, 
pain, blood flow and chemical balance. Afferent fibers reach the lamina I of the spinal 
cord grey matter, and from there projections carry information to structures in the 
brainstem, notably the nucleus of the solitary tract (NTS), parabrachial nucleus (PBN) 
and periaqueductal grey (PAG). These structures are involved in homeostatic regulation 
and are believed to be essential to interoceptive sensation, as their lesioning can result in 
coma (Damasio & Carvalho, 2013). This group of posterior brainstem structures projects 
to the thalamus, which in turn relays information to the insula, believed to be the main 
hub of integration of interoceptive and exteroceptive sensations (Critchley & Harrison, 
2013). As the insula is widely cortically connected, interoceptive information can 
interface with diverse brain regions, notably the somatosensory cortices, anterior 
cingulate cortex, amygdala and ventromedial prefrontal cortex. These structures are 
intimately linked to phenomena such as emotion, cognitive control, decision-making and 
salience processing, and recent evidence has substantiated a link between interoception 
and these cognitive domains (Dunn et al., 2010; Chong, Ng, Lee & Zhou, 2017). 
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The vagus nerve, i.e., the second major afferent pathway for interoception, carries 
information primarily about pulmonary, cardiovascular and gastrointestinal systems 
(Damasio & Carvalho, 2013). Projections carry information from the vagus nerve to the 
NTS, and subsequently to the higher brainstem structures such as PAG and PBN and the 
hypothalamus. Thereafter they are once again integrated in the insular cortex.  A third 
pathway exists, bypassing the brainstem, directly through the area postrema, which is a 
chemosensory structure dealing mainly with homeostatic regulation of metabolic 
processes, and which has been implicated in cardiovascular regulation. 
Measurement of interoceptive ability can take many forms, ranging from self-report 
questionnaires to objective measures of interoceptive accuracy. Perhaps the most 
widespread are heartbeat detection and tracking tasks, which have the advantage of being 
concerned with cardiac processes, a class of physiological response that has been 
experimentally and intuitively implicated in emotional experience. A cardiac response is 
a well documented consequence of viewing emotional stimuli, and interoceptive ability in 
particular has been found to mediate the intensity of perceived emotions (Wiens et al., 
2000). Heartbeat tasks have several advantages over other tasks that probe interoception, 
primarily ease of measurement, as well as cardiac activity being amenable to 
experimental manipulation. These tasks can be broken down into two distinct types. 
Heartbeat detection involves comparing the presentation of auditory tones with the 
heartbeat to determine whether the two are coincident or offset (Whitehead, Drescher, 
Heiman, & Blackwell, 1977). It has been widely used (Critchley & Garfinkel, 2015), 
performance on it well characterized, and has the advantage of being immune to 
participants’ knowledge of typical heart rates. The major drawback of heartbeat detection 
tasks is consistently low performance, which typically rises only slightly above chance 
level (Khalsa et al, 2009). 
A second category of cardiovascular interoceptive tasks includes heartbeat tracking. This 
type of task involves participants counting their heartbeats (without feeling their pulse) 
during a predetermined time window not disclosed to the participant. Typical 
administration parameters involve time windows of 25, 35 and 45 seconds. This type of 
task, although easier to administer and amenable to better performance, suffers from 
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several major drawbacks, including few trials and the possibility of a participant using 
prior knowledge of their heart rate to estimate, rather than individually perceive, their 
heartbeat (Khalsa et al., 2009). The link between interoception and memory judgments 
reported by Fiacconi et al. (2017) was obtained using a heartbeat counting task. In the 
present study, we utilized both tasks in order to allow for a more comprehensive 
assessment of individual variation in interoceptive ability, and to determine whether our 
experimental manipulation has differential effects on the different types of heartbeat 
tracking measures. 
The approach of correlating individual differences in interoception with other cognitive 
processes, although widely used, suffers from the typical drawbacks of correlational 
research. Although it presents a promising way of identifying areas in which 
interoception may be involved, this approach falls short in establishing whether 
interoception plays a causal role in the processes being studied. In order to make strong 
claims about the directionality, and indeed the presence of a causal relationship, 
interoception must be experimentally manipulated. 
Several methods for manipulating interoception have been proposed and used in the past. 
Common methods include utilizing a tilt table to change body position between 
horizontal and vertical, as well as engaging participants in dynamic and isometric 
exercise, such as stationary cycling or isometric hand grip. Position changes from vertical 
to horizontal and physical exertion activate the sympathetic nervous system, and have 
been associated with an increase in interoceptive accuracy as indexed by both heartbeat 
detection and heartbeat tracking tasks (Pollatos et al., 2007; Schandry, Bestler & 
Montoya, 1993; Ring, Liu & Brener, 1994). Although these methods are widely used and 
non-invasive, they do not give insight into the neurochemistry or specific pathways 
involved in the relationship between influences on cardiac response and interoceptive 
ability. 
Perhaps the paradigm most amenable to careful experimental control to date, reported by 
Khalsa et al. (2009), employs isoproterenol, a beta-adrenergic agonist that raises heart 
rate and is used in clinical settings primarily to treat bradycardia and heart block via its 
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action to increase heart rate by stimulation of beta-adrenergic receptors in the heart. By 
adapting an established clinical threshold test for experimental settings, Khalsa and 
colleagues were able to achieve an incremental and carefully controlled dose-dependent 
heart rate increase. This increase was transient, lasting only as long as intravenous 
isoproterenol was administered, and could be maintained by continued administration. 
Khalsa and colleagues observed an increase in interoceptive awareness, indexed by real-
time self-report ratings of heartbeat and breathing sensation intensity, corresponding to 
increasing doses of isoproterenol (and thus to increasing heart rate). 
In addition to being amenable to very precise control over the resulting physiological 
effect, this pharmacological manipulation is distinguished from the aforementioned 
methods by its ability to probe not just the possible effect of interoception on a cognitive 
process, but also the physiological means through which this effect may be carried out. 
By considering which receptors and signalling pathways are affected by the drug, it is 
possible to make inferences about the physiological substrate and neurochemistry of 
interoception’s involvement in cognition. However, despite its strengths, this paradigm 
suffers from the major drawback of being difficult to administer. Intravenous infusion 
requires the supervision of a nurse, and increased risk to participants. We therefore 
sought to pursue less invasive pharmacological means of heart rate manipulation. 
A promising pharmacological candidate is propranolol, a beta-adrenergic antagonist. 
Propranolol was chosen for this initial study for several reasons. First, it is considered to 
be safe for administration in non-clinical research settings; second, it has documented 
robust and controllable effects on heart rate (Chamberlain et al., 2006); and third, it is 
thought to have limited effects on overall cognitive performance (Chamberlain & 
Robbins, 2013). 
Propranolol is typically prescribed for high blood pressure, and off label for performance 
anxiety. With the administration of a single dose, it induces a drop in heart rate and blood 
pressure. Propranolol reaches peak plasma concentration at around 90 minutes after 
administration, making it a viable candidate for use with research studies. Its effects are 
relatively short lived, with a half life of 3-4 hours (Hurlemann et al., 2005). Side effects 
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are not typically associated with a one-time dose as used in research, and in a wide array 
of studies, research participants were not able to reliably identify the drug and placebo 
conditions. In the context of research studies, propranolol is typically administered in 
doses of 20-80 mg, with the resulting drop in heart rate of around 5 bpm for 20 mg and 
increasing with the dose (Chamberlain & Robbins, 2013). We used a 20mg dose because 
preliminary piloting revealed a robust reduction in heart rate even at this low dose. 
One of the major advantages of this drug for future use with cognitive paradigms is the 
rich literature documenting its lack of effect on general cognitive function. Multiple 
studies have reported negative results on attentional and memory tasks (Chamberlain & 
Robbins, 2013; Chamberlain et al., 2006). In a meta-analysis (Chamberlain & Robbins, 
2013), only one study found that a higher (40 mg) dose impaired attention on an 
attentional blink paradigm (De Martino, Strange & Dolan, 2008), while most showed 
negative results. Results on working memory are mixed, although there is evidence that 
propranolol in particular (as opposed to peripherally acting beta-blockers) has detrimental 
effects, especially in participants with low anxiety (Chamberlain et al., 2006). Because 
propranolol is a beta-adrenergic antagonist, in contrast to the agonist isoproterenol, we 
expect that by lowering heart rate it will decrease interoceptive awareness, thus lowering 
interoceptive accuracy. To control for potential effects of the drug on global cognitive 
processes, we included two cognitive control tasks that mimic the interoception tasks in 
structure without invoking their interoceptive component. 
In the current study, we hypothesized that i) a single 20 mg dose of propranolol will 
result in a measurable physiological response, indexed by a drop of heart rate by about 5 
bpm; ii) performance on the heartbeat interoception tasks will be lower in the drug than 
the placebo condition; iii) performance on non-interoceptive cognitive control tasks will 
not be different between drug and placebo conditions. 
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Chapter 2  
2 Methods 
2.1 Session structure and drug administration 
We conducted a double-blind, randomized, placebo-controlled crossover study, in which 
each participant completed two 2.5 hour sessions, one under propranolol and the other 
under placebo. Drug/placebo order was counterbalanced across participants. The drug 
condition involved ingesting a 20 mg oral capsule of propranolol; the placebo capsule 
contained corn starch. In keeping with the double-blind nature of the study, the pill 
packets were prepared and coded by a separate member of the lab. Sessions were 
conducted at the same time of day, with a washout period of 7 days in-between. The 
washout period was chosen to be in keeping with other cognitive propranolol studies, as 
well as be at least 10x the elimination half-life of propranolol (3-4 hours; Hurlemann et 
al., 2005). 
Session structure is illustrated in Figure 1. The procedure for both sessions was identical 
except where noted. Each session started with consent (1st session only), ECG setup and 
Questionnaire Set 1 (State anxiety, Bond-Lader visual analogue scale, and in the 1st 
session only, Trait anxiety). This was followed by ingestion of the capsule, the first of the 
physiological measurements, and immediately the first block of tasks. The task block 
included both interoception tasks and both control tasks. ECG recordings were made 
during the interoception tasks. The interoception task order was randomized, and each 
interoception task was followed by its corresponding control task. The second task block 
repeated the 4 tasks from the first block, in the same order, and was timed to be centered 
around the time of peak drug effect at 90 minutes after ingestion. The order of tasks was 
kept constant between the two sessions for any given participant. The 2nd task block was 
followed by Questionnaire Set 2 (State anxiety and Bond-Lader visual analogue scale). 
Physiological measurements (blood pressure and heart rate) were obtained every 10 
minutes over the course of 2 hours following ingestion, for a total of 13 measurements. 
Additional measures were included near the middle of the session (“Additional 
9 
Measures” in Figure 1) for exploratory purposes, and are not considered in the current 
investigation. 
 
Figure 1: Session structure. Each participant completed both a drug session and a 
placebo session. Both sessions followed the same format (except where noted). 
Following set-up, each session began with Questionnaire Set 1 (“Q1”: Alertness, State 
anxiety and, in the first session only, Trait anxiety) and administration of the capsule 
(designated as time=0 minutes). Capsule ingestion was immediately followed by Task 
Block 1 (“Tasks 1”), which consisted of both interoception tasks and both control tasks. 
Around the time of peak drug effect (at time=90 minutes), all behavioural tasks were 
repeated in Task Block 2 (“Tasks 2”), followed by State anxiety and Alertness in 
Questionnaire Set 2 (“Q2”). Additional measures (“Additional Measures”) were included 
in the middle of both sessions for exploratory purposes and are not considered in the 
present investigation. The light green bar represents the course of the drug effect in the 
drug session, starting with ingestion at t=0 and peaking at t=90 minutes. Physiological 
measures consisted of heart rate and blood pressure, and were taken every 10 minutes 
(indicated by teal arrows) starting at capsule ingestion, for a total of 13 measurements. 
2.2 Participants 
Thirteen young adults (23.8 (SD=3.1) years of age, with 18.8 (SD=3.1) years of 
education; 5 female) were recruited by poster from the Western University community. 
Participants were monetarily compensated for their time. Exclusion criteria included any 
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history of cardiovascular, neurological or psychiatric conditions, any contraindications to 
propranolol, resting blood pressure below 90/60 mmHg and resting heart rate below 60 
bpm. The study was approved by the Health Sciences Research Ethics Board at Western 
University. Not all tasks were completed by every participant (n=12 for heartbeat 
tracking; n=9 for seconds counting; n=8 for one-back; n=13 for heartbeat detection and 
all self-report measures) 
2.3 Experimental setup 
ECG recordings were made using three Ag/AgCl electrodes in a Lead II configuration, 
and a BIOPAC MP150 MRI-compatible system connected to a BIOPAC ECG100C-MRI 
amplifier (BIOPAC Systems, Goleta, CA). The signal was acquired at a sampling rate of 
2000 Hz and bandpass filtered at 1-35 Hz. AcqKnowledge software (Biopac Systems 
Inc.) was used to record the ECG signal and, for the tone-matching task, calculate R-
wave onsets in real time. The R-wave onsets were then relayed to the testing computer 
running E-Prime 2.0 (Psychology Software Tools, Pittsburgh, PA) in order to trigger 
heartbeat-dependent acoustic tone presentation.  
2.4 Behavioural tasks 
2.4.1 Interoception tasks 
2.4.1.1 Heartbeat detection 
A tone matching (Whitehead et al., 1977) task was used, in which a series of tones were 
presented through a speaker that matched the participant’s heart rate in speed and pattern. 
Tones were either coincident with each heartbeat or were offset by 500ms. This was 
achieved by simultaneous recording of the ECG signal. AcqKnowledge software was 
used to detect R-peaks in real time and this signal was relayed back to the testing 
computer in order to trigger an acoustic tone, with or without delay. Each trial consisted 
of a series of ten tones, after which the participant was prompted to indicate whether the 
series was  synchronous or asynchronous with the heartbeat. There were 60 trials in total, 
and performance was assessed as the percent of trials correctly classified (chance is 
50%). 
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2.4.1.2 Heartbeat tracking 
A commonly used heartbeat counting paradigm was employed (Schandry, 1981). 
Participants were asked to count their heartbeats within a certain period of time (without 
feeling for their pulse). There were 6 trials in total, with durations of 25s, 35s and 45s, 
twice each. A veridical heartbeat count during each period was obtained via ECG. 
Performance was assessed as Percent Accuracy = (counted heartbeats)/(actual 
heartbeats), averaged over all 6 trials. 
2.4.2 Cognitive control tasks 
A concern with any apparent change in performance on interoception tasks is whether the 
effect is due to a change in interoceptive ability, or some other cognitive process, for 
example, a decrease in global attentional capacity. In order to rule out this alternative 
interpretation, we included two cognitive control tasks, performed as close in time as 
possible to the interoception tasks. Any global effects on cognition as a result of drug 
administration or other effects over the course of the sessions should be reflected in 
performance on these tasks.  
2.4.2.1 One-back task 
An auditory one-back task was administered in which participants listened to a series of 
letters of the alphabet spoken on a recording, and were asked to press a button each time 
the same letter appeared on two consecutive trials. There were 10 different letters 
presented over 90 trials in total. Back-to-back repeats were considered target trials and 
represented 25% of all trials. Accuracy was recorded as percent targets detected. The 
One-back task was administered on a Dell XPS 13 laptop running Windows 10 and 
custom Matlab code using Psychtoolbox (Brainard, 1997; Pelli, 1997; Kleiner et al, 
2007). This task was included as a control task for the tone-matching interoception task. 
It was intended to probe auditory vigilance and sustained attention. 
2.4.2.2 Seconds counting task 
This procedure was identical to the heartbeat counting task, but participants were asked to 
count the number of seconds (without the aid of a clock) instead of heartbeats. 
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Performance was assessed as for the heartbeat counting task. This task was meant to 
mimic the cognitive demands of the heartbeat counting task as closely as possible, 
without engaging interoceptive processes. 
2.5 Self-report measures 
2.5.1 Anxiety 
To assess individual differences in anxiety, as well as to track changes in anxiety over the 
course of testing, we administered the State and Trait Anxiety Inventory (STAI; 
Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983). This is a widely used inventory 
consisting of two scales: trait anxiety, meant to assess stable individual differences in 
anxiety, and state anxiety, which indexes anxious disposition at a given moment and can 
be administered several times over the course of testing. This measure was included 
because both propranolol’s effects and individual differences in interoception have been 
linked to anxiety (Steenen et al., 2016; Critchley et al., 2004). Including these scales 
allowed us to assess the impact of individual differences in this important characteristic 
on our tasks and manipulation, both in terms of stable differences in personality, and 
potential differences in how participants may react to the drug or the experimental 
paradigm itself. 
2.5.2 Alertness 
To index alertness throughout the testing sessions we used the Alertness subscale of the 
Bond-Lader Visual Analogue Mood Scale (BL-VAS; Bond & Lader, 1974). Because 
decreases in alertness can be a side effect of clinical propranolol use, as well as of 
lengthy experimental paradigms, including a measure of alertness around the time of task 
performance allowed us to assess the contribution of this factor to any change in 
behavioural performance in our study. 
2.6 Processing of physiological data 
ECG recordings and e-Prime data files were processed using custom Matlab R2014b 
code (The Mathworks, Natick, MA). ECG recordings obtained during the heartbeat 
counting tasks were run through custom Matlab code that counted the number of 
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heartbeats by identifying local maxima (R-peaks) above a certain amplitude threshold 
(which was manually determined for each participant to ensure clean separation of R-
peaks from the rest of the ECG signal). 
2.7 Statistical analyses 
Statistical analyses were performed using Matlab and R (R Development Core Team, 
2015). Time-dependent trends in physiological measurements (heart rate and blood 
pressure) were assessed by fitting a linear model to the measurements obtained during the 
sessions. T-tests were used to check for differences between conditions at the time of 
peak drug effect and averaged over a 40-minute window centered around same. The 40-
minute window was selected because it encompassed the fairly lengthy battery of 
behavioural tasks meant to be performed around the time of peak drug effect. 
To determine whether propranolol or the session structure had any effect on outcomes for 
the self-report measures and behavioural tasks, we asked two questions: 1. Did drug 
treatment result in different performance at the 2nd measure (outcome), when accounting 
for baseline performance? 2. Was there a systematic difference between conditions, or a 
systematic change in performance over the course of both sessions? 
To determine whether any differences in outcome scores existed between drug and 
placebo conditions, we performed an ANCOVA analysis by fitting a model of the form: 
(Ydrug-Yplacebo)~(Xdrug-Xplacebo), where Ydrug and Yplacebo are outcome measures in the drug 
and placebo conditions, respectively, and Xdrug and Xplacebo are baseline measures for 
same. This approach has been shown to have the most sensitivity in taking advantage of 
the strengths of a 2x2 crossover design, and is especially relevant for studies with small 
samples (Metcalfe, 2010; Mehrotra, 2014). The ANCOVA was performed in conjunction 
with stepwise regression using the Akaike Information Criterion to identify covariates 
that contributed to outcome performance beyond the contribution of baseline measures 
included in the base model. For the behavioural tasks, the covariates considered were: 
task order (indexing the order of interoception tasks), session order (indexing 
drug/placebo order assignment), trait anxiety scores and difference in state anxiety 
outcome scores. For the self-report measures, only trait anxiety scores and session order 
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were considered. ANCOVA results are reported only for the model identified by stepwise 
regression as having the best fit. 
To determine whether performance changed over the course of the sessions, and to 
confirm that performance did not differ systematically between drug and placebo 
conditions, a repeated measures ANOVA was conducted to assess main effects of time 
and condition. 
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3 Results 
3.1 Physiological response 
3.1.1 Heart rate 
Mean heart rate, recorded at 13 time points during each session, is presented in Figure 2. 
Linear regression was performed to assess the effect of the drug manipulation on heart 
rate (Figure 3). Propranolol reliably lowered participants’ heart rate over time (β=-1.22, 
p=1.59×10-11). A weaker negative relationship was also observed in the placebo condition 
(β=-0.43, p=0.0462), indicative of participants settling into their resting heart rate over 
the course of a sedentary testing session. The degree of change reported for propranolol is 
thus likely a combination of the settling effect in addition to the action of the drug. 
Baseline heart rate, as measured at the time of ingestion, did not differ between 
conditions (placebo M=69.4, SD=12.1; drug M=70.8, SD=9.6; t(12)=-0.41, p=0.69). 
Important for the present study, a significant difference in heart rate was confirmed 
between the placebo and drug conditions after the drug had time to take effect. This was 
confirmed at the time of peak drug effect 90 minutes after ingestion (placebo M=65.9, 
SD=10.3; drug M=60.1, SD=8.9; t(12)=2.83, p=0.0151, Figure 4A), and over a time 
window of 70-110 minutes after ingestion (placebo M=65.4, SD=10.0; drug M=59.5, 
SD=7.7; t(12)=2.83, p=0.0068, Figure 4B). The latter time window was isolated for 
analysis because it fully encompasses the battery of tasks performed in the second half of 
the session. The presence of a significant difference in heart rate during this time window 
indicates that the drug manipulation was effective while the tasks were being performed. 
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Figure 2: Heart rate measurements. Thirteen measurements were taken in total. 
Measurement 1 was taken at the time of ingestion, and measurement 10 was timed to the 
peak of drug activity, 90 minutes after ingestion. Error bars are standard error of the 
mean. Baseline heart rate did not differ between conditions (placebo M=69.4, SD=12.1; 
drug M=70.8, SD=9.6; t(12)=-0.41, p=0.69). 
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Figure 3: Linear regression of heart rate over time for the placebo (A) and drug (B) 
conditions. A significant negative trend was observed for both conditions (β=-0.43, 
p=0.0462 for placebo; β=-1.22, p=1.59×10-11 for drug). 
 
Figure 4: Heart rate at and around peak drug effect. Heart rate was found to be 
significantly lower in the drug, compared to the placebo, condition at both (A) the time of 
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peak drug effect (placebo M=65.9, SD=10.3; drug M=60.1, SD=8.9; t(12)=2.83, 
p=0.0151) and (B) during the 70-110 minute time window encompassing the second 
battery of tasks (placebo M=65.4, SD=10.0; drug M=59.5, SD=7.7; t(12)=2.83, 
p=0.0068). 
3.1.2 Blood pressure 
Mean systolic and diastolic blood pressure measurements are presented in Figure 5. 
Systolic blood pressure was found to decrease over the course of the session in the drug 
(β=-0.529, p=0.0236, Figure 6B), but not the placebo condition (β=0.088, p=0.684, 
Figure 6A). However, even at the time of peak drug effect, a significant difference could 
not be statistically confirmed for systolic blood pressure (t(12)=0.316, p=0.757). A 
significant decrease in diastolic blood pressure was not detected in either the drug (β=-
0.27, p=0.0833, Figure 6D) or the placebo condition (β=0.103, p=0.54, Figure 6C).  
 
Figure 5: Average systolic (A) and diastolic (B) blood pressure over the course of 
both sessions. Error bars are standard error of the mean (SEM). 
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Figure 6: Linear regression of blood pressure over time for the placebo (A, C) and 
drug (B, D) conditions. Systolic blood pressure was found to decrease over the course of 
the session in the drug (β=-0.529, p=0.0236), but not the placebo condition (β=0.088, 
p=0.684). Diastolic blood pressure was not found to decrease in the drug (β=-0.27, 
p=0.0833) or the placebo condition (β=0.103, p=0.54). 
3.2 Self-report measures 
3.2.1 Trait and state anxiety 
Self-report and behavioural measure outcomes are presented in Table 1. Trait anxiety was 
assessed at the beginning of the first session (Figure 7). The average score reported by the 
participants in the present study was 38.15 (SD 11.19), which is in agreement with norms 
for this measure based on samples of healthy adults (M=34.8, SD=9.2 for women and 
M=34.9, SD=9.2 for men; Spielberger et al., 1983). Baseline measures of state anxiety 
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(Figure 8) were similarly typical, 30.85 (SD 8.64) for the placebo session and 31.85 (SD 
10.7) for the drug session (typical means are M=35.2, SD=10.6 for women and M=35.7, 
SD=10.4 for men; Spielberger et al., 1983). An ANCOVA was performed on the 
difference between outcome scores, with baseline score difference as a covariate, in order 
to assess differences in outcome between conditions. Outcome state anxiety did not differ 
between conditions (intercept=2.97, p=0.119), and stepwise regression did not detect a 
significant contribution of either trait anxiety or session order as covariates. No effect of 
condition (F(1, 12)=2.683, p=0.127) or time (F(1, 2)=0.048, p=0.831) on state anxiety 
measures was found, and no time x condition interaction was observed (F(1, 12)=0.582, 
p=0.46) using repeated measures ANOVA. 
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Table 1: Baseline and outcome scores on self-report and behavioural measures. 
 Placebo Drug 
 Baseline 
Mean(SD) 
Outcome 
Mean(SD) 
Baseline 
Mean(SD) 
Outcome 
Mean(SD) 
State anxiety 
(total) 
30.85 (8.64) 30.15 (10.06) 31.85 (10.7) 33.08 (9.3) 
Alertness 
(total) 
61.21 (17.83) 49.05 (22.46) 61.17 (20.48) 56.21 (19.41) 
Tone matching 
(% accuracy) 
57.05 (11.02) 56.28 (11.75) 57.05 (10.43) 54.23 (8.21) 
Heartbeat 
counting 
(% accuracy) 
71.26 (15.44) 77.2 (11.24) 71.34 (15.32) 79.95 (10.37) 
One-back 
(% accuracy) 
82.39 (20.1) 89.2 (5.92) 97.73 (2.43) 88.64 (12.86) 
Seconds 
counting 
(% accuracy) 
69.48 (12.59) 72.24 (14.15) 72.59 (14.91) 70.53 (14.09) 
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Figure 7: Trait anxiety. Participants reported mean trait anxiety scores of 38.15 (SD 
11.19). Trait anxiety was assessed once, at the beginning of the first session for each 
participant. The scores obtained in this sample are in agreement with norms based on 
samples of healthy adults (M=34.8, SD=9.2 for women and M=34.9, SD=9.2 for men; 
Spielberger et al., 1983). 
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Figure 8: State anxiety mean scores (A) and individual paired-data plots (B). Error 
bars are standard error of the mean. There was no effect of condition (F(1, 12)=2.683, 
p=0.127) or time (F(1, 2)=0.048, p=0.831) on state anxiety measures, and no time x 
condition interaction (F(1, 12)=0.582, p=0.46). 
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3.2.2 Alertness 
ANCOVA analysis using a model that included only baseline score differences as a 
covariate found that outcome alertness scores were not significantly different between 
conditions (intercept=7.1912, p=0.0987). Stepwise regression confirmed that models 
including trait anxiety scores and session order as covariates did not predict the outcome 
variable better (AIC=71.13 for best model), and the best model was found to explain 
51.87% of the variance in outcome measures (coefficient=0.8305, R2=0.5187, p=0.005). 
Repeated measures ANOVA revealed that alertness decreased over the course of both 
testing sessions (main effect of time, F(1, 12) = 6.11, p=0.0236), and no Time x 
Condition interaction was observed (F(1, 12) = 3.403, p=0.0899), Figure 9).  
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Figure 9: Alertness mean scores (A) and individual paired-data plots (B). Errors bars 
are standard error of the mean. Alertness decreased over the course of both testing 
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sessions (main effect of time, F(1, 12) = 6.11, p=0.0236). No time x condition interaction 
was observed (F(1, 12) = 3.403, p=0.0899) 
3.3 Behavioural tasks 
3.3.1 Interoception tasks 
3.3.1.1 Heartbeat detection 
Outcome performance on the tone matching task was not found to differ significantly 
between the drug and placebo conditions (intercept=-20.07, p=0.113), as assessed by 
ANCOVA; however, performance in the drug session was numerically lower (Figure 10). 
Stepwise regression assessed the contribution of task order, session order, outcome state 
anxiety and trait anxiety as covariates. The best performing model included outcome state 
anxiety and trait anxiety in addition to baseline task performance (AIC=63.55). However, 
the overall model did not predict outcome tone matching scores (R2=0.4132, p=0.1688). 
There was no main effect of either time (F(1, 12)=0.649, p=0.436) or condition (F(1, 
12)=0.196, p=0.666), and no significant interaction (F(1, 12)=0.244, p=0.63), as assessed 
by repeated measures ANOVA. 
It should be noted that 8 of 13 subjects failed to achieve above-chance baseline 
performance in both conditions. When these subjects are excluded, visual inspection of 
the resulting plot (Figure 10C) shows that every remaining subject exhibited a decrease in 
performance over the course of the drug condition, but not the placebo condition. 
Statistical analyses are not presented for this small sub-sample. 
A post-hoc power analysis revealed that, based on the effect size observed in our limited 
sample (f2=0.7), a sample of 25 participants would be needed to detect a difference in 
outcome scores between conditions at an alpha level of 0.05, with a power of 0.9.   
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Figure 10: Tone matching (heartbeat detection) mean performance (A), individual 
paired-data plots (B) and individual paired-data plots for good performers (C). 
Errors bars are standard error of the mean. Outcome performance on the tone matching 
task was found not to differ significantly between the drug and placebo conditions 
(intercept=-20.07, p=0.113); however, performance in the drug session was numerically 
lower. Only 5 subjects achieved above-chance performance at baseline in both 
conditions, and their data are plotted separately (C). The numerical trend observed in the 
overall sample appears to be more pronounced in the sub-sample of good performers, in 
that decreases in performance appear to be stronger in the drug condition. Statistical 
analyses were not performed on this sub-sample. 
3.3.1.2 Heartbeat tracking 
Heartbeat counting performance did not differ significantly between conditions 
(ANCOVA; intercept=0.027, p=0.437). Stepwise regression did not identify task order, 
session order, trait anxiety or outcome state anxiety as additional covariates beyond 
baseline task performance (best model AIC= -49.66). The resulting model did not 
significantly predict heartbeat counting outcome scores (R2=0.057, p=0.453). 
A repeated measures ANOVA revealed a significant main effect of time on outcome 
heartbeat counting scores (F(1, 11)=10.21, p=0.009), indicating that for both conditions, 
performance improved at the second measurement (Figure 11). This is in opposition to 
the tone matching results, which, although not statistically significant, were numerically 
lower under the influence of the drug than at the beginning. No significant main effect of 
condition (F(1, 11)=0.255, p=0.624), nor a condition x time interaction (F(1, 11)=0.363, 
p=0.559), was observed. 
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Figure 11: Heartbeat counting (tracking) task performance mean performance (A) 
and individual paired-data plots (B). Errors bars are standard error of the mean. A 
significant main effect of time on outcome heartbeat counting scores was observed (F(1, 
11)=10.21, p=0.009), indicating that performance increased over time in both sessions. 
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No significant main effect of condition (F(1, 11)=0.255, p=0.624), nor a condition x time 
interaction (F(1, 11)=0.363, p=0.559), was observed. Heartbeat counting performance did 
not differ significantly between conditions (ANCOVA; intercept=0.027, p=0.437). 
3.3.2 Cognitive control tasks 
3.3.2.1 One-back task 
ANOVA did not identify a main effect of either condition(F(1,7)=2.8, p=0.138) or 
time(F(1,7)=0.054, p=0.822) on task performance, and no significant interaction of time 
x condition was found (F(1, 7)=4.455, p=0.0727). However, it should be noted that 
performance on this task was frequently at or near ceiling (Figure 12), which can mask 
potential effects on performance. In particular, the homogeneity of slopes assumption is 
violated when the sample includes baseline scores at ceiling. ANCOVA was thus not 
performed on data from this task. Additionally, there was no difference in baseline scores 
(t(7)=-2.04, p=0.0812). 
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Figure 12: One-back task performance mean performance (A) and individual 
paired-data plots (B). Errors bars are standard error of the mean. Several participants 
exhibited near-ceiling performance.  There was no main effect of either condition 
(F(1,7)=2.8, p=0.138) or time (F(1,7)=0.054, p=0.822) on task performance, and no 
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significant interaction of time x condition (F(1, 7)=4.455, p=0.0727). There was no 
difference in baseline scores (t(7)=-2.04, p=0.0812). 
 
3.3.2.2 Seconds counting 
Performance on the seconds counting task did not appear to be affected by the drug 
manipulation, or significantly change throughout the session (Figure 13). No significant 
difference in outcome scores for the seconds counting task was observed via ANCOVA 
using the base model that included a covariate of baseline performance only (intercept=-
0.029, p=0.123). Stepwise regression did not identify a significant contribution from task 
order, session order, outcome state anxiety or trait anxiety, beyond baseline performance 
(best model AIC=-52.78). The final model, which included baseline performance only, 
accounted for 49.23% of the variance in the outcome measure (R2=0.4923, p=0.03515). 
A repeated measures ANOVA revealed no main effects of time (F(1, 8)=0.19, p=0.895) 
or condition (F(1, 8)=0.065, p=0.805), or time x condition interaction (F(1, 8)=3.115, 
p=0.116). 
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Figure 13: Seconds counting task performance mean performance (A) and 
individual paired-data plots (B). Errors bars are standard error of the mean. No 
significant difference in outcome scores for the seconds counting task was observed 
(intercept=-0.029, p=0.123). The final regression model, which included baseline 
performance only, accounted for 49.23% of the variance in the outcome measure 
(R2=0.4923, p=0.03515). A repeated measures ANOVA revealed no main effects of time 
(F(1, 8)=0.19, p=0.895) or condition (F(1, 8)=0.065, p=0.805), or time x condition 
interaction (F(1, 8)=3.115, p=0.116). 
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4 Discussion 
The primary goal of the present study was to identify whether propranolol is a promising 
agent for the manipulation of interoceptive processes. We conducted a double-blind 
crossover study, in which we assessed the effects of 20 mg of propranolol on 
physiological response, two measures of interoceptive ability, self-reported anxiety and 
alertness, as well as two cognitive control tasks. We found that propranolol produced a 
reliable decrease in heart rate, compared to placebo, as well as a decrease in systolic 
blood pressure. Propranolol numerically decreased interoceptive performance on the tone 
matching interoception task, although this effect did not reach statistical significance. In 
contrast, on the heartbeat counting task performance improved with time in both 
conditions. No effect of drug on self-report measures was found, but alertness was 
observed to decrease over time in both conditions. Finally, propranolol had no effect on 
performance on either cognitive control task. 
4.1 Physiological effects 
Propranolol, at a dose of 20 mg administered orally, elicited an expected and reliable 
physiological response. Participants demonstrated a significant drop in heart rate of 
nearly 6 bpm in the drug, compared to the placebo, condition, thus confirming the 
effectiveness of our pharmacological manipulation. This finding is in line with other 
studies reporting an approximately 5 bpm decrease for 20 mg, and somewhat higher 
decreases (10-15 bpm) for 40 and 80 mg (Chamberlain & Robbins, 2013; Chamberlain et 
al., 2006). Although doses of 40 and 80 mg are much more common in the cognitive 
propranolol literature, our findings demonstrate that even a 20 mg dose produces reliable 
heart rate changes, statistically detectable even in a small sample. Our findings thus 
confirm a reliable effect of propranolol at low dose, which is in line with its medicinal 
use, where a dosage of 10 mg is common. We further confirmed that heart rate displayed 
a linear downward trend over time, and that the drop in heart rate was reliable not just at 
the time of peak drug effect, but in a 40-minute window around the peak, which 
encompassed administration of our tasks of interest. This finding suggests that the drug 
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effect is reliable over the time course of reasonably long experimental paradigms, and 
that this is achievable even with a dose considerably smaller than what is typically used. 
In addition to an effect on heart rate, we found an effect of the drug on systolic blood 
pressure. This is in line with propranolol’s known action and concordant with findings 
from other studies, which frequently report drops in systolic blood pressure, and 
occasionally diastolic (Kroes et al., 2010; Kroes et al., 2015; Tollenaar et al., 2009; 
Schwabe et al., 2012; Hurlemann et al., 2005; van Stegeren, Evaraerd & Gooren, 2002). 
It is worth noting that although our findings are similar, the dose used in our study (20 
mg) is considerably smaller than those used in most other studies (40-80 mg), and in fact, 
a study conducted using a 20 mg dose reported minimal drops in blood pressure (De 
Martino et al., 2008). This discrepancy may largely be due to differences in protocol. Our 
conclusions are based on regression analysis, made possible through frequent 
measurements that were taken every 10 minutes throughout the session. In contrast, most 
published studies collected physiological measurements at only a few time points, and 
performed a statistical contrast typically only at the time of peak drug effect. In fact, in 
our own analysis, t-tests failed to confirm a statistically reliable difference at peak, 
highlighting the benefits of repeated measurement over extended time periods for 
detection of small effects. These findings confirm the utility of incorporating frequent 
physiological measurements into any propranolol paradigm, and caution against 
interpreting any results as a consequence of heart rate changes alone in terms of 
physiological mechanisms. Even though the observed downward trends in blood pressure 
are small, and the differences at any particular time point likely of minimal clinical 
significance, the presence of these trends confirms that propranolol’s mechanisms of 
action on blood pressure are engaged even by a small dose. In light of this, care should be 
taken in deriving mechanistic conclusions that separate the drug’s effects on heart rate 
from its effects on blood pressure. 
4.2 Effects on interoception 
Although we predicted that performance on both interoception tasks should decrease 
under the effect of propranolol, we found that outcome performance changed in different 
directions for the two tasks. Heartbeat counting performance improved over the course of 
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both the drug and the placebo sessions, whereas tone matching performance showed a 
numerical decrease for the drug session alone. If borne out in a larger sample, this finding 
would be indicative of the presence of different mechanisms of action, or different 
strategies used by participants. This would be in line with existing research showing that 
the two interoception tasks may engage different strategies. Furthermore, prior research 
on the link between beta-adrenergic mechanisms and interoception has focused on 
interoceptive awareness, rather than accuracy (Khalsa et al., 2009). 
Propranolol, whose action is in opposition to agonists such as isoproterenol, known to 
intensify interoceptive sensations (Khalsa et al., 2009), can be reasonably expected to 
cause a decrease in interoceptive awareness; however, the resulting effect on 
interoceptive accuracy is not necessarily clear-cut. Although it is reasonable to suppose 
that decreasing sensitivity would lead to more interoceptive errors, it has been shown that 
interoceptive awareness only partially predicts interoceptive accuracy (Garfinkel et al., 
2015). This could reflect a true partial independence between these processes, or possibly 
be a consequence of measurement strategies. Since interoceptive awareness is measured 
through self-report, whereas interoceptive accuracy is measured objectively, it is possible 
for the two not to concur. In fact, discrepancies have been observed in previous studies, 
which have noted that even good performance on objective measures of interoceptive 
accuracy is often accompanied by subjective reports to the contrary (Wiens, 2005). 
It is also possible that a drop in interoceptive awareness could trigger compensatory 
mechanisms, or an over-reliance on alternative strategies, which can alter overall task 
performance in unexpected ways. In fact, using an estimate of one’s heart rate, rather 
than engaging in beat-by-beat heartbeat counting, has been identified as an alternative 
strategy for the heartbeat counting task (Khalsa et al., 2009; Kleckner et al., 2015). While 
participants’ ability to detect their heartbeat is assumed not to change throughout the 
placebo session, their estimate of their heart rate can certainly improve, as most of the 
experimental session consists of tasks that effectively gather heart rate information for the 
participant. Thus, the heartbeat counting task appears to be susceptible to within-session 
practice effects, and it is possible that this improvement can mask any changes in 
moment-to-moment interoceptive ability if participants switch over to estimation 
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strategies towards the end of the session. This would produce a pattern of results exactly 
as seen: an overall increase in heartbeat counting performance over time, regardless of 
condition, that does not align with tone matching performance (where estimation 
strategies are patently of no use). 
Task order was not found to contribute significantly to explaining variability in heartbeat 
counting outcome scores. This indicates that the strategy used for heartbeat counting did 
not depend on having been explicitly exposed to heart rate information immediately 
before the task - i.e. hearing their heartbeat in the form of auditory tones as part of the 
tone matching task did not seem to affect participants’ performance on heartbeat 
counting. This would be of particular concern if participants were relying on estimation 
strategies. This could be indicative that they are not, or, in light of the observed practice 
effect, that they could be hitting an information ceiling even without a specific 
contribution of the auditory feedback from the tone matching task. It is worth noting, 
also, that the tone matching task is notoriously difficult (Kleckner et al., 2015) and 
typically commands all of a participant’s attention, making at least explicit additional 
strategies less likely. 
Although the numerical decrease in performance on the tone matching task for the drug 
condition failed to reach statistical significance at the 5% alpha level, the numerical 
change and corresponding statistical reliability (p=0.113) of the effect suggests it could 
be worth exploring with a larger sample. Since this task is less susceptible to alternative 
strategies than heartbeat counting (Khalsa et al., 2009; Kleckner et al., 2015), it seems 
likely that this result is more indicative of the actual effect, if any, of propranolol on 
interoceptive ability. A post hoc power analysis revealed that, based on the effect size 
observed in this limited sample, a relatively modest sample of 25 participants would be 
needed to detect it with good statistical power. This result suggests that this effect is a 
good candidate for follow-up in a larger sample. 
It is important to note that this task is known to be exceptionally difficult, resulting in 
high rates of below-chance performance (Khalsa et al., 2009). This seems to have been an 
issue in our study, as well, with 8 out of 13 participants failing to perform above chance 
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at the beginning of both sessions. With this in mind, it would be sensible to limit the 
analysis only to participants who achieved above-chance performance at baseline in both 
conditions. The present study’s sample is too small for this to be a viable statistical query, 
however, visual inspection of the individual participant plots (Figure 10C) suggests that 
the decrease in performance for the drug condition may possibly be more pronounced in 
this subgroup. In fact, every subject who started above baseline in the drug condition 
experienced a drop in performance (whereas the same cannot be said for the placebo 
session). The present investigation used a relatively small sample size with the purpose of 
validating our proposed pharmacological manipulation and identifying avenues for future 
exploration. Therefore, the numerical effect seen in this task, as well as the trends 
observed within the subgroup of good performers, are taken as warranting further 
investigation, and given the reasonable sample size suggested by the power analysis, will 
be followed up by a larger study aiming for a total sample of 25. 
4.3 Effects on state anxiety 
A surprising finding in the present study was a lack of effect of propranolol on state 
anxiety, as assessed by pre- and post-drug self-report questionnaires. This finding runs in 
opposition to other studies that have found anxiolytic effects for propranolol, even at 
doses as low as 10 mg (Steenen et al., 2016; Mealy et al., 1996), as well as to its off-label 
use in treating performance anxiety. A potential explanation is that participants in the 
present study were specifically screened to have no history of clinical anxiety diagnosis, 
as confirmed by the finding that for our sample the trait and state scores were within the 
typical range. Additionally, the testing session was not an anxiogenic situation. Finally, it 
is possible that the nature of the tasks in the present study may have interacted with the 
anxiolytic effects of the drug (Domschke et al., 2010). It is even possible that detecting a 
change in one’s own heart rate could have increased state anxiety for some individuals. 
(Indeed, the largest change from baseline to outcome was an increase observed for one 
participant in the drug condition, and was more than twice the magnitude of any other 
pre-post change on state anxiety in the study.) The lack of effect in the present study can 
be taken to indicate that a change in state anxiety is unlikely to account for the present 
findings, either on the interoception or the control tasks. It is worth noting that 
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interactions between anxiety and cognitive performance under propranolol have been 
noted with respect to other tasks (Chamberlain et al., 2006), so caution should be taken in 
extrapolating these findings to other paradigms. 
4.4 Effects on alertness 
Alertness was found to decrease over time in both conditions. This is an expected finding, 
since each testing session lasted 2.5 hours with minimal breaks. No effect of condition on 
alertness was found, indicating that any decreases in performance on the behavioural 
tasks for the drug condition cannot be explained as a result of lower alertness alone. From 
a methodological perspective, this finding also confirms that although decreased alertness 
is a known side-effect of propranolol used chronically, this is not an issue in the context 
of a single dose administered to healthy, low-risk individuals in the context of a research 
study. This finding further points to the viability of propranolol for future research work. 
4.5 Effects on cognitive control tasks 
Neither control task exhibited a reliable difference in outcome performance between 
conditions, confirming that any differences in interoception task performance cannot be 
simply due to a global detrimental or facilitatory effect of propranolol. Because the 
seconds counting task did not exhibit the same increase in performance over time as 
heartbeat counting, we can reasonably conclude that the mechanism responsible for the 
heartbeat counting performance increase could be specific to interoception, whether or 
not it is sensitive to the propranolol manipulation.  
No significant effects were observed on the one-back task. However, this result should be 
interpreted with caution, as performance on this task was at or near ceiling for many 
participants, which can mask effects of practice or drug on performance. Although this 
task was originally included in the study as a conceptual parallel to the tone matching 
task, in that it functions effectively as an auditory vigilance control task, our findings 
indicate that it is not a suitable control. Especially considering the level of difficulty of 
the tone matching task, the near-ceiling performance on the one-back task renders it a 
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poor point of reference with respect to cognitive performance. If this or a similar task is 
to be included in future studies, the difficulty level will need to be increased substantially. 
4.6 Mechanisms of action 
If the numerical decrease observed on the tone matching task in the drug condition, and 
its independence of effects on cognitive control tasks, are confirmed in a larger sample, 
these results will indicate the involvement of beta-adrenergic signalling in interoception. 
While propranolol’s dual action on both central and peripheral pathways ensures that 
neither route’s potential effects are missed in this initial investigation, in order to 
elucidate the precise mechanism of beta-adrenergic signalling in interoception, further 
follow-up work utilizing more selective agents will be necessary. However, some 
speculation can be made even at this point, based on existing evidence. In particular, it 
does not seem to be the case that lower heart rate generally results in lower interoception 
performance. A relevant analysis was performed by Kleckner and colleagues (2015), who 
conducted a study in which 174 participants performed the tone matching task employed 
here. The authors found no correlation between resting heart rate and interoceptive 
ability, as indexed by the tone matching task. This suggests that a slow heart rate alone is 
not enough to limit interoceptive ability. It is, however, possible that a slower heart rate, 
as deviation from a person’s habitual baseline, may still have an effect. This effect could 
be to decrease interoceptive ability by attenuating the heart rate signal, or on the contrary, 
to be perceived as being more salient, and result in an increase of interoceptive ability. 
Our preliminary results suggest that the former is more likely, however, more 
investigation is needed. 
The mechanisms of propranolol’s action on interoception, and more generally, that of 
beta-adrenergic blockade, are certain to be complex. The involvement of at least some 
peripheral mechanisms, i.e. action on the heart rate directly, which in turn affects 
downstream interoceptive processes in the brain, is very likely, possibly in addition to 
central mechanisms. The primary evidence for this suggestion is the effect of hydrophilic, 
peripherally acting isoproterenol on interoceptive awareness (Khalsa et al., 2009), and the 
predominance of beta-adrenergic receptors peripherally, relative to the brain (Szabadi, 
2013). Additionally, the anxiolytic effects of propranolol are believed to be largely 
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peripheral, acting by blocking the autonomic arousal associated with specific anxiogenic 
triggers, rather than changing brain chemistry more chronically (Steenen et al., 2016). 
Because propranolol does cross the blood-brain barrier, central mechanisms concerning 
the action of noradrenaline within the brain itself must also be considered. There is some 
evidence that the action of propranolol on working memory is due to such central 
mechanisms, as peripherally acting beta-blockers such as atenolol have not been shown 
to impair working memory. Similarly, while propranolol has been shown to affect 
encoding of emotional memories, hydrophilic beta-blockers do not exhibit the same 
influence, thus implicating propranolol’s central effects in its influence on emotional 
memory (Rimmele et al., 2016; Chamberlain et al., 2006). This effect has been linked to 
the presence of beta-adrenergic receptors in the amygdala (Szabadi, 2013). Although the 
same is not known with certainty for the insula, it is important to note that beta-
adrenergic receptors have been found in the human brain in other areas relevant to 
interoceptive signalling, such as the thalamus and basal ganglia (Reznikoff et al., 1986). 
Additionally, a recent study found that intra-insular injections of propranolol in rats 
affected arousal-related behaviour (Rojas et al., 2015). In the same study, intra-insular 
injections of norepinephrine were found to interact with the effects of oral propranolol, 
confirming central action in the insula following oral administration in rats. Thus, 
although strong empirical evidence exists for the modulation of interoception by 
peripheral effects of beta-adrenergic signalling, the possibility exists that propranolol’s 
central effects could extend to interoceptive systems. 
4.7 Limitations 
The above conclusions must be considered in light of the present study’s design and 
limited sample size. Although this limitation is mitigated by our use of a crossover 
design, which gives more power than the between-subjects designs used by the majority 
of cognitive propranolol studies, care must still be taken in interpreting these preliminary 
findings. In particular, nonsignificant, but interesting, results are presented here as 
indications that further investigation is warranted, rather than hard evidence in 
themselves. Similarly, the negative results presented must be also be interpreted with 
caution, keeping in mind that the present study can be underpowered to detect small 
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behavioural effects. This is especially important when null effects alter the interpretation 
of the main findings, as in the case of null effects of propranolol on cognitive control 
tasks 
4.8 Future directions 
Follow-up studies with agents more selective than propranolol are needed to disentangle 
potential mechanistic pathways involved in the influence of beta-adrenergic agents on 
interoception. A promising candidate agent is atenolol, whose effects, while similar to 
propranolol, are confined to peripheral pathways due to its nearly absent penetrance of 
the blood brain barrier. Although studies utilizing isoproterenol have already implicated 
peripheral mechanisms in the control of interoceptive sensitivity, employing atenolol 
would provide important evidence regarding the effects of attenuating, rather than 
increasing, cardiac activity. Furthermore, considerable insight is to be gained by 
conducting parallel studies with propranolol and atenolol. By utilizing identical 
paradigms while varying only the drug used, and calibrating the doses for identical 
degrees of physiological response, it would be possible to obtain a quantitative 
comparison of the differential contributions of central-cum-peripheral, versus solely 
peripheral, mechanisms to any observed effect on interoception. A quantitative contrast 
of this nature would thus give some idea of the degree of contribution of central 
mechanisms alone. 
A robust and safe paradigm for manipulating interoception, as well as a mechanistic 
understanding of its action, would be a great asset in investigating the contribution of 
interoception to other cognitive processes. Such a paradigm would be invaluable in 
establishing a causal link between interoception and non-emotional cognition, such as 
metamemory. The present study represents a promising start, in terms of both 
establishing a viable paradigm for administering propranolol in the context of 
interoceptive accuracy measures and their associated control tasks, as well as providing 
tentative evidence for an effect of beta-adrenergic blockade on interoceptive accuracy. 
Although much work remains to be done to confirm these effects, the paradigm presented 
in this study represents a viable platform for this investigation, as well as a foundation for 
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follow-up work with more selective pharmacological agents and additional cognitive 
tasks. 
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